Monitor for final Phase 2 data readout and formal initiation of the Phase 3 trial, which could serve as a catalyst; watch for financing activity given the company's small market cap and likely need for capital to fund late-stage trials.
Price Chart
Executive Summary
AIM ImmunoTech announced an agreement with Thermo Fisher Scientific's PPD clinical research unit to design a Phase 3 trial for Ampligen in late-stage pancreatic cancer, based on promising Phase 2 DURIPANC trial data showing positive progression-free survival, overall survival, and safety signals. The move signals advancement toward late-stage development for a high-unmet-need indication, though no final efficacy data or regulatory approvals have been achieved yet.
Key Facts
- AIM ImmunoTech is partnering with Thermo Fisher Scientific’s PPD to design a Phase 3 trial for Ampligen in late-stage pancreatic cancer.
- The decision follows promising interim results from the ongoing Phase 2 DURIPANC trial, including Progression-Free Survival (PFS), Overall Survival (OS), and safety data.
- The Phase 2 trial is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands, enrolling up to 25 patients.
- AIM views pancreatic cancer as its highest-potential indication and has updated its corporate strategy accordingly.
- No final clinical results, efficacy endpoints, or regulatory approvals have been announced; the program remains in development.
Financial Impact
Potential long-term value if Phase 3 succeeds, but no near-term financial impact; significant future funding likely required
Risk Factors
- Phase 2 data is preliminary and based on a small, single-center study with only up to 25 subjects.
- No guarantee that Phase 3 trial will be initiated, funded, or successful.
- High risk of dilution given AIM's $4M market cap and capital-intensive nature of Phase 3 development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247438 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers